Payment overview · 2025
General Payments
$3,974.38
160 reported records · 31 companies
Healthcare provider profile · identity verified
Robert D Pintauro, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BRONX, NY · NPI 1942393343
Verified facts
What the public records show
CMS Open Payments records show Robert D Pintauro, M.D. received $3,974.38 in general payments during 2025 across 160 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 8.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 54 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Vraylar, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Lokelma by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 263 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $354.31 | 8.9% | 16 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $314.64 | 7.9% | 14 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $305.75 | 7.7% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $285.15 | 7.2% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $271.20 | 6.8% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $257.35 | 6.5% | 14 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $245.90 | 6.2% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $221.53 | 5.6% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $173.81 | 4.4% | 9 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $153.97 | 3.9% | 5 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $153.75 | 3.9% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $144.76 | 3.6% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $136.57 | 3.4% | 7 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $121.91 | 3.1% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $119.62 | 3.0% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $105.54 | 2.7% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $100.99 | 2.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $89.05 | 2.2% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $65.48 | 1.6% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $63.00 | 1.6% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $44.44 | 1.1% | 2 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $43.96 | 1.1% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $29.92 | 0.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.99 | 0.6% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $23.87 | 0.6% | 1 | 2025 |
| Cumberland Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.94 | 0.6% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.02 | 0.6% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.38 | 0.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.95 | 0.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.61 | 0.5% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.02 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,974.38 | 160 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $305.75 | 14 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $264.20 | 10 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $263.92 | 15 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $245.90 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $245.40 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $218.70 | 11 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $209.12 | 9 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $193.89 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $173.38 | 9 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $162.38 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $161.05 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $158.38 | 8 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $153.97 | 5 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $153.97 | 5 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $153.97 | 5 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $153.75 | 6 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $121.91 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $119.62 | 5 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $114.32 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $105.54 | 4 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $100.99 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $92.74 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $89.05 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $83.97 | 5 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $82.88 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $82.88 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $66.45 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $65.48 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $63.00 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $62.08 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $62.08 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $60.12 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $57.60 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $57.60 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $55.07 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $54.80 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $44.44 | 2 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $43.96 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $29.92 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $27.04 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $26.66 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $26.00 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $24.99 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| KRISTALOSE Normalized: kristalose |
Drug | Cumberland Pharmaceuticals, Inc. | $22.94 | 1 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $22.02 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.95 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| ONZETRA XSAIL Normalized: onzetra xsail |
Drug | Currax Pharmaceuticals LLC | $14.68 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $7.33 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $4.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 32 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 263 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 117 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 46 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 64 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 95 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 47 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
117 | 30 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
47 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
64 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
50 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
95 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
32 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
263 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 848 | 113 |
| Amlodipine Besylate | Amlodipine Besylate | 581 | 87 |
| Metoprolol Tartrate | Metoprolol Tartrate | 298 | 41 |
| Levothyroxine Sodium | Levothyroxine Sodium | 292 | 49 |
| Metformin Hcl | Metformin Hcl | 277 | 49 |
| Losartan Potassium | Losartan Potassium | 273 | 61 |
| Lisinopril | Lisinopril | 268 | 43 |
| Mirtazapine | Mirtazapine | 266 | 22 |
| Eliquis | Apixaban | 263 | 36 |
| Furosemide | Furosemide | 242 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 234 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 225 | 26 |
| Gabapentin | Gabapentin | 207 | 32 |
| Nifedipine Er | Nifedipine | 150 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 145 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 135 | 11 |
| Omeprazole | Omeprazole | 134 | 43 |
| Carvedilol | Carvedilol | 131 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 127 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 123 | 20 |
| Memantine Hcl | Memantine Hcl | 119 | 13 |
| Farxiga | Dapagliflozin Propanediol | 117 | 30 |
| Finasteride | Finasteride | 112 | suppressed |
| Levetiracetam | Levetiracetam | 108 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 107 | 22 |
| Latanoprost | Latanoprost | 107 | 14 |
| Sertraline Hcl | Sertraline Hcl | 102 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 22 |
| Ozempic | Semaglutide | 95 | 28 |
| Januvia | Sitagliptin Phosphate | 91 | suppressed |
| Lactulose | Lactulose | 90 | 13 |
| Trazodone Hcl | Trazodone Hcl | 87 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 86 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 83 | 13 |
| Famotidine | Famotidine | 82 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 82 | 23 |
| Allopurinol | Allopurinol | 79 | 13 |
| Potassium Chloride | Potassium Chloride | 74 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 73 | 13 |
| Montelukast Sodium | Montelukast Sodium | 70 | 16 |
| Donepezil Hcl | Donepezil Hcl | 68 | suppressed |
| Clonazepam | Clonazepam | 66 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 66 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 65 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 11 |
| Mounjaro | Tirzepatide | 64 | 18 |
| Simvastatin | Simvastatin | 64 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 63 | 29 |
| Lokelma | Sodium Zirconium Cyclosilicate | 61 | suppressed |
| Tradjenta | Linagliptin | 59 | suppressed |
| Spironolactone | Spironolactone | 54 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 53 | suppressed |
| Ezetimibe | Ezetimibe | 53 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | suppressed |
| Methotrexate | Methotrexate Sodium | 51 | suppressed |
| Linzess | Linaclotide | 50 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | 16 |
| Trulicity | Dulaglutide | 50 | 13 |
| Bupropion Xl | Bupropion Hcl | 48 | suppressed |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | 17 |
| Jardiance | Empagliflozin | 46 | 13 |
| Lorazepam | Lorazepam | 46 | 17 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 45 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 44 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 42 | suppressed |
| Meloxicam | Meloxicam | 41 | 19 |
| Brimonidine Tartrate | Brimonidine Tartrate | 40 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 40 | 15 |
| Mupirocin | Mupirocin | 40 | suppressed |
| Atenolol | Atenolol | 39 | suppressed |
| Methimazole | Methimazole | 39 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 39 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 38 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 37 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Chlorthalidone | Chlorthalidone | 36 | suppressed |
| Budesonide | Budesonide | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | 11 |
| Divalproex Sodium | Divalproex Sodium | 33 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Valsartan | Valsartan | 33 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 32 | 32 |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Lamotrigine | Lamotrigine | 32 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 31 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 30 | suppressed |
| Metolazone | Metolazone | 29 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 29 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 28 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Risperidone | Risperidone | 26 | suppressed |
| Vascepa | Icosapent Ethyl | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 20 |
| Calcium Acetate | Calcium Acetate | 24 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Timolol Maleate | Timolol Maleate | 22 | suppressed |
| Alprazolam | Alprazolam | 21 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Prednisone | Prednisone | 18 | suppressed |
| Silodosin | Silodosin | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 17 |
| Dilt-Xr | Diltiazem Hcl | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Procrit | Epoetin Alfa | 17 | suppressed |
| Acitretin | Acitretin | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 15 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Repatha Pushtronex | Evolocumab | 15 | suppressed |
| Tacrolimus | Tacrolimus | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Lumigan | Bimatoprost | 14 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,974.38 · 160 records | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, ABRYSVO, AIRSUPRA, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, CONTRAVE, Cologuard Collection Kit, DUPIXENT, Dexcom G6 Transmitter, EDARBI, ELIQUIS, ENTRESTO, EVENITY, FANAPT, FARXIGA, FASENRA, GEMTESA, GLYCATE, GVOKE HYPOPEN, General - Therapies, IBSRELA, JARDIANCE, KISUNLA, KRISTALOSE, Kerendia, LEQVIO, MOUNJARO, NEXLETOL, NURTEC ODT, NUZYRA, ONZETRA XSAIL, OTEZLA, Ozempic, PREVNAR 20, PROLIA, Paradise Ultrasound Renal Denervation System, QULIPTA, RELTONE 200 MG, RELTONE 400 MG, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, VYNDAQEL, Veozah, Wegovy, ZAVZPRET, ZENPEP, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error